Harvard Bioscience (HBIO) Competitors

Thermo Fisher Scientific (NYSE:TMO) and Harvard Bioscience (NASDAQ:HBIO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.

Which has more risk and volatility, TMO or HBIO?

Thermo Fisher Scientific has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Does the MarketBeat Community believe in TMO or HBIO?

Thermo Fisher Scientific received 715 more outperform votes than Harvard Bioscience when rated by MarketBeat users. Likewise, 80.94% of users gave Thermo Fisher Scientific an outperform vote while only 72.02% of users gave Harvard Bioscience an outperform vote.

Company	Underperform	Outperform
Thermo Fisher Scientific	Outperform Votes 1083 80.94%	Underperform Votes 255 19.06%
Harvard Bioscience	Outperform Votes 368 72.02%	Underperform Votes 143 27.98%

Is TMO or HBIO more profitable?

Thermo Fisher Scientific has a net margin of 14.78% compared to Harvard Bioscience's net margin of -14.57%. Thermo Fisher Scientific's return on equity of 17.51% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	14.78%	17.51%	8.52%
Harvard Bioscience	-14.57%	-4.64%	-2.40%

Do institutionals & insiders hold more shares of TMO or HBIO?

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by insiders. Comparatively, 9.0% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Does the media refer more to TMO or HBIO?

In the previous week, Thermo Fisher Scientific had 74 more articles in the media than Harvard Bioscience. MarketBeat recorded 76 mentions for Thermo Fisher Scientific and 2 mentions for Harvard Bioscience. Thermo Fisher Scientific's average media sentiment score of 1.49 beat Harvard Bioscience's score of 0.10 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	67 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harvard Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has better valuation and earnings, TMO or HBIO?

Thermo Fisher Scientific has higher revenue and earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$42.88B	4.75	$6.34B	$16.53	32.22
Harvard Bioscience	$112.25M	0.38	-$3.41M	-$0.33	-3.00

Do analysts prefer TMO or HBIO?

Thermo Fisher Scientific currently has a consensus target price of $658.00, suggesting a potential upside of 23.56%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities research analysts clearly believe Thermo Fisher Scientific is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.82
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Thermo Fisher Scientific beats Harvard Bioscience on 16 of the 18 factors compared between the two stocks.